Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3060% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Precision BioSciences's ebitda for the twelve months ending Jun 30, 2026 was -$35.15M. For fiscal 2025 it was -$50.68M. The highest annual figure on record is -$22.76M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.68M | – |
| FY2024 | Dec 31, 2024 | -$22.76M | – |
| FY2023 | Dec 31, 2023 | -$36.92M | – |
| FY2022 | Dec 31, 2022 | -$54.51M | – |
| FY2021 | Dec 31, 2021 | -$30.40M | – |
| FY2020 | Dec 31, 2020 | -$101.05M | – |
| FY2019 | Dec 31, 2019 | -$81.89M | – |
| FY2018 | Dec 31, 2018 | -$45.56M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.78M | – |
| Q4 FY2025 | Dec 31, 2025 | $12.85M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.50M | -185.2% |
| Q1 FY2025 | Mar 31, 2025 | -$21.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.56M | – |
| Q2 FY2024 | Jun 30, 2024 | $25.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.74M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.63M | -215.1% |
| Q1 FY2022 | Mar 31, 2022 | -$25.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.55M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.28M | – |
| Q2 FY2021 | Jun 30, 2021 | $24.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$30.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.05M | – |
| Q3 FY2019 | Sep 30, 2019 | -$20.58M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.70M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.56M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.86M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.61M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.78M | – |
See a number that looks wrong?